Jeffrey Magallanes Gamboa

Dr. Jeffrey Magallanes Gamboa


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
Enrique RodillaEnrique Rodilla
Enrique Rodilla
MLMaría D. López-Carmona
María D. López-Carmona
XCXavier Cortés
Xavier Cortés
LCLidia Cobos-Palacios
Lidia Cobos-Palacios
SCSergio Canales
Sergio Canales
FNFor The Semi-Covid-19 Network
For The Semi-Covid-19 Network
Older age and cardiovascular comorbidities are well-known risk factors for all-cause mortality in patients with coronavirus disease 2019 (COVID-19). Hypertension and age are the 2 principal determinants of arterial stiffness (AS). This study aimed to estimate AS in patients with COVID-19 requiring hospitalization and analyze its association with all-cause in-hospital mortality. This observational, retrospective, multicenter cohort study analyzed 12 170 patients admitted to 150 Spanish centers included in the SEMI-COVID-19 Network. We compared AS, defined as pulse pressure ≥60 mm Hg, and clinical characteristics between survivors and nonsurvivors. Mean age was 67.5 (±16.1) years and 42.5% were women. Overall, 2606 (21.4%) subjects died. Admission systolic blood pressure (BP) <120 and ≥140 mm Hg was a predictor of higher all-cause mortality (23.5% and 22.8%, respectively, P <0.001), compared with systolic BP between 120 and 140 mm Hg (18.6%). The 4379 patients with AS (36.0%) were older and had higher systolic and lower diastolic BP. Multivariate analysis showed that AS and systolic BP <120 mm Hg significantly and independently predicted all-cause in-hospital mortality (adjusted odds ratio [ORadj]: 1.27, P =0.0001; ORadj: 1.48, P =0.0001, respectively) after adjusting for sex (males, ORadj: 1.6, P =0.0001), age tertiles (second and third tertiles, ORadj: 2.0 and 4.7, P =0.0001), Charlson Comorbidity Index (second and third tertiles, ORadj: 4.8 and 8.6, P =0.0001), heart failure, and previous and in-hospital antihypertensive treatment. Our data show that AS and admission systolic BP <120 mm Hg had independent prognostic value for all-cause mortality in patients with COVID-19 requiring hospitalization.

15 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMaría Mateos González
María Mateos González
EGElena Sierra Gonzalo
Elena Sierra Gonzalo
ILIrene Casado Lopez
Irene Casado Lopez
FAFrancisco Arnalich
Francisco Arnalich
JPJosé Luis Beato Pérez
José Luis Beato Pérez
FNFor The Semi-Covid-19 Network
For The Semi-Covid-19 Network
Objectives: A decrease in blood cell counts, especially lymphocytes and eosinophils, has been described in patients with serious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), but there is no knowledge of their potential role of the recovery in these patients’ prognosis. This article aims to analyse the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Design: This work was a retrospective, multicentre cohort study of 9644 hospitalised patients with confirmed COVID-19 from the Spanish Society of Internal Medicine’s SEMI-COVID-19 Registry. Setting: This study examined patients hospitalised in 147 hospitals throughout Spain. Participants: This work analysed 9644 patients (57.12% male) out of a cohort of 12,826 patients ≥18 years of age hospitalised with COVID-19 in Spain included in the SEMI-COVID-19 Registry as of 29 May 2020. Main outcome measures: The main outcome measure of this work is the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Univariate analysis was performed to determine possible predictors of death, and then multivariate analysis was carried out to control for potential confounders. Results: An increase in the eosinophil count on the seventh day of hospitalisation was associated with a better prognosis, including lower mortality rates (5.2% vs. 22.6% in non-recoverers, OR 0.234; 95% CI, 0.154 to 0.354) and lower complication rates, especially regarding the development of acute respiratory distress syndrome (8% vs. 20.1%, p = 0.000) and ICU admission (5.4% vs. 10.8%, p = 0.000). Lymphocyte recovery was found to have no effect on prognosis. Treatment with inhaled or systemic glucocorticoids was not found to be a confounding factor. Conclusion: Eosinophil recovery in patients with COVID-19 who required hospitalisation had an independent prognostic value for all-cause mortality and a milder course.

21 July 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
CGCarles Garcia-Cervera
Carles Garcia-Cervera
VGVicente Giner-Galvañ
Vicente Giner-Galvañ
PWPhilip E Wikman-Jorgensen
Philip E Wikman-Jorgensen
JLJaime Laureiro
Jaime Laureiro
MRManuel Rubio-Rivas
Manuel Rubio-Rivas
JAJuan Miguel Anton-Santos
Juan Miguel Anton-Santos

19 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JDJesús Díez-Manglano
Jesús Díez-Manglano
MSMarta Nataya Solís-Marquínez
Marta Nataya Solís-Marquínez
AGAndrea Álvarez García
Andrea Álvarez García
NANicolás Alcalá-Rivera
Nicolás Alcalá-Rivera
IRIrene Maderuelo Riesco
Irene Maderuelo Riesco
FNFor The Semi-Covid-19 Network
For The Semi-Covid-19 Network
Aim: To determine whether healthcare workers (HCW) hospitalized in Spain due to COVID-19 have a worse prognosis than non-healthcare workers (NHCW). Methods: Observational cohort study based on the SEMI-COVID-19 Registry, a nationwide registry that collects sociodemographic, clinical, laboratory, and treatment data on patients hospitalised with COVID-19 in Spain. Patients aged 20–65 years were selected. A multivariate logistic regression model was performed to identify factors associated with mortality. Results: As of 22 May 2020, 4393 patients were included, of whom 419 (9.5%) were HCW. Median (interquartile range) age of HCW was 52 (15) years and 62.4% were women. Prevalence of comorbidities and severe radiological findings upon admission were less frequent in HCW. There were no difference in need of respiratory support and admission to intensive care unit, but occurrence of sepsis and in-hospital mortality was lower in HCW (1.7% vs. 3.9%; p = 0.024 and 0.7% vs. 4.8%; p<0.001 respectively). Age, male sex and comorbidity, were independently associated with higher in-hospital mortality and healthcare working with lower mortality (OR 0.211, 95%CI 0.067–0.667, p = 0.008). 30-days survival was higher in HCW (0.968 vs. 0.851 p<0.001). Conclusions: Hospitalized COVID-19 HCW had fewer comorbidities and a better prognosis than NHCW. Our results suggest that professional exposure to COVID-19 in HCW does not carry more clinical severity nor mortality.

1 February 2020 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
JDJesús Díez-Manglano
Jesús Díez-Manglano
SPSoledad Isasi de Isasmendi Pérez
Soledad Isasi de Isasmendi Pérez
RFRosa Fenoll
Rosa Fenoll
LSLuis Ángel Sánchez
Luis Ángel Sánchez
VGVicente Giner Galvañ
Vicente Giner Galvañ
JIJosé María Pascual Izuel
José María Pascual Izuel

21 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MGMaría Mateos González
María Mateos González
EGElena Sierra Gonzalo
Elena Sierra Gonzalo
ILIrene Casado Lopez
Irene Casado Lopez
FAFrancisco Arnalich
Francisco Arnalich
JPJose Luis Beato Perez
Jose Luis Beato Perez
JAJuan Miguel Anton-Santos
Juan Miguel Anton-Santos
Objectives: A decrease in blood cell counts, especially lymphocytes and eosinophils, has been described in patients with severe SARS-CoV-2 (COVID-19), but there is no knowledge of the potential role of their recovery in these patients’ prognosis. This article aims to analyse the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Design: This work is a multicentre, retrospective, cohort study of 9,644 hospitalised patients with confirmed COVID-19 from the Spanish Society of Internal Medicine’s SEMI-COVID-19 Registry. Setting: This study examined patients hospitalised in 147 hospitals throughout Spain. Participants: This work analysed 9,644 patients (57.12% male) out of a cohort of 12,826 patients ≥18 years of age hospitalised with COVID-19 in Spain included in the SEMI-COVID-19 Registry as of 29 May 2020. Main outcome measures: The main outcome measure of this work is the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Univariate analysis was performed to determine possible predictors of death and then multivariate analysis was carried out to control for potential confounders. Results: An increase in the eosinophil count on the seventh day of hospitalisation was associated with a better prognosis, including lower mortality rates (5.2% vs 22.6% in non-recoverers, OR 0.234 [95% CI, 0.154 to 0.354]) and lower complication rates, especially regarding to development of acute respiratory distress syndrome (8% vs 20.1%, p=0.000) and ICU admission (5.4% vs 10.8%, p=0.000). Lymphocyte recovery was found to have no effect on prognosis. Treatment with inhaled or systemic glucocorticoids was not found to be a confounding factor. Conclusion: Eosinophil recovery in patients with COVID-19 is a reliable marker of a good prognosis that is independent of prior treatment. This finding could be used to guide discharge decisions.